BWAY's strong revenue and earnings growth are tempered by an earnings-quality red flag, a failed asymmetry gate after the stock already reached its price target, and recent insider selling.
Thesis pillars
- Earnings Quality Red Flag→Stable
- Strong Growth Profile→Stable
- Target Reached Negative Asymmetry↑Improving
- +1 more pillar — see the Why tab for full reasoning
Brainsway Ltd. (BWAY) Stock Analysis
Breakout setup
Healthcare · Medical Devices
Wait for pullback to $15.05. BUY gates pass at $16.95, but analyst target reached - limited upside remaining and near 52-week high (2.6% away) argue for a more patient entry. Engine's entry $15.05 (Default 5pct Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum.
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious and... Read more
Wait for pullback to $15.05. BUY gates pass at $16.95, but analyst target reached - limited upside remaining and near 52-week high (2.6% away) argue for a more patient entry. Engine's entry $15.05 (Default 5pct Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Chart setup: Golden cross, above all MAs, RSI 56, MACD bullish. Maintain position. Not compelling to add more. | News modifier +1 (HOLD_IF_HOLDING → STRONG_BUY_WAIT) Score 6.3/10, moderate confidence.
Passes 8/9 gates (positive momentum, clean insider activity, no SEC red flags, news boost earnings 0.80, news boost analyst 0.70, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
Recent developments
updated 2026-08-13Recent Developments — Brainsway Ltd.
Latest news
- NEWS Brainsway (NASDAQ:BWAY) Stock Price Up 13% on Analyst Upgrade - MarketBeat — MarketBeat positive
- NEWS BrainsWay Shares Rise After Higher Q2 Results - marketscreener.com — marketscreener.com positive
- NEWS BWAY Maintains Buy Rating by BTIG -- Price Target Raised to $20. - GuruFocus — GuruFocus positive
- NEWS Brainsway stock price target raised to $20 by BTIG on revenue beat - Investing.com — Investing.com positive
- NEWS Brainsway (NASDAQ:BWAY) Posts Earnings Results, Misses Estimates By $0.03 EPS - MarketBeat — MarketBeat negative
Generated 2026-08-14T11:47:19Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker·1 ceiling hit
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Wait for pullback to $15.05. BUY gates pass at $16.95, but analyst target reached - limited upside remaining and near 52-week high (2.6% away) argue for a more patient entry. Engine's entry $15.05 (Default 5pct Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Chart setup: Golden cross, above all MAs, RSI 56, MACD bullish. Maintain position. Not compelling to add more. | News modifier +1 (HOLD_IF_HOLDING → STRONG_BUY_WAIT) Target $19.49 (+15.0%), stop $13.03 (−30.1%), A.R:R -0.8:1. Score 6.3/10, moderate confidence.
Take-profit target: $19.49 (-11.4% upside). Target $19.49 (+15.0%), stop $13.03 (−30.1%), A.R:R -0.8:1. Stop-loss: $13.03.
Analyst target reached - limited upside remaining; Near 52-week high (2.6% away).
Brainsway Ltd. trades at a P/E of 66.4 (forward 34.1). TrendMatrix value score: 4.0/10. Verdict: Buy (Wait for Entry).
7 analysts cover BWAY with a consensus score of 4.3/5. Average price target: $18.
What does Brainsway Ltd. do?BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United...
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious and late-life depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post-traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. The company was founded in 2003 and is headquartered in Jerusalem, Israel.